Hepatocellular Cancer

P=N/A, N=10, Terminated, University of Aberdeen | Unknown status --> Terminated; The project did not progress as there were no findings available for the lab analysis of microRNA expression.

Moreover, low RAD18 expression predicted a favorable response to immune checkpoint blockade therapy, while its high expression correlated with anti-PD-1 resistance in triple-negative breast cancer. Collectively, our findings identify RAD18 as a potential pan-cancer prognostic biomarker and immunotherapeutic target, with targeting RAD18 holding promise for reversing immunotherapy resistance in solid tumors.

AARS2 links lactate metabolism to HCC progression via lactylation. Kukoamine A nanotherapy targeting this axis shows synergistic efficacy with immunotherapy, advancing the prospects of precision oncology.

Given the advanced stage of disease, systemic immunotherapy with tremelimumab and durvalumab was initiated. This case underscores the critical role of a multimodal diagnostic approach in atypical presentations of HCC to enable accurate diagnosis and appropriate therapeutic decision-making.

A non-genetic state recapitulating the transcriptional footprint associated with CTNNB1 mutation identifies wild-type HCCs characterized by unfavorable survival outcomes and immune-excluded tumor immune microenvironment.

In conclusion, HBV-induced alterations in these transcription factors represent critical oncogenic mechanisms in HCC. Further research is essential to develop novel therapeutic approaches that regulate their activity, ultimately improving clinical outcomes for patients.

In this study, SP94-LCP/DOX&Bcl-2 siRNA was successfully prepared. It exhibited remarkable targeting ability and antitumor activity, significantly enhancing the therapeutic effect of doxorubicin and siRNA on HCC. The construction of this drug delivery system provided a novel strategy for the clinical treatment of HCC.

METTL14 overexpression protects against radiation-induced hepatocyte injury primarily through modulation of apoptosis and ferroptosis pathways, with HMOX1 and SERPINE1 serving as key downstream effectors. Targeting the METTL14-SERPINE1- miR-145-5p axis may offer a novel therapeutic strategy for RILD.

In HCC mouse models, BCAT1-deficient TAMs aggravate tumor burden and suppress CD8+ T cell-mediated antitumor immunity, while myeloid-specific BCAT1 overexpression or adoptive transfer of BCAT1+ macrophages stimulates the antitumor immune response and improves anti-PD1 therapy responses. In summary, our data support a BCAT1-mediated regulation of crotonate-dependent epigenetic modulation of immunosuppressive TAMs in HCC, and indicate BCAT1+ macrophages as an adjuvant treatment for enhancing immune checkpoint blockade therapy.

Its combination with PD-L1 blockade further increased suppression to 78.3%, with enhanced CD8+ T cell infiltration and antibody production. Collectively, these findings establish L1-LNPs/HGPC3C mRNA as a promising immunotherapeutic approach for HCC treatment and its combination with immune checkpoint blockade holds clinical translational potential.

Furthermore, AS-IV suppressed T-2 toxin-triggered apoptosis by modulating the BAX/BCL-2 ratio, inhibiting cytochrome c release, and attenuating caspase activation. Together, these findings indicate that AS-IV protects HepG2 cells from T-2 toxin-induced cytotoxicity by maintaining mitochondrial homeostasis and suppressing the intrinsic apoptotic pathway, providing mechanistic evidence for its protective effect.

This supramolecular platform integrates the photothermal switch and delivery carriers and precisely controls RNA editing in vivo, avoiding potential systemic toxicity induced by off-target delivery. Our study establishes a programmable and precise RNA regulation platform in vivo by means of supramolecular assembly for safe, tunable, and effective RNA-based cancer therapy.